RxDoctor Payments Data

Janet Hummer, MD

Ophthalmology · Indianapolis, INNPI 1336180181

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $81,125 of the $95,621 with a category attached, or 84.8%. Regeneron Healthcare Solutions, Inc. accounts for 90.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $32,337 and has fallen 59.1% since, to $13,218 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,621in general payments, 2019–2025

Across 146 payments — averaging $654.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$86K
  • Novartis$7K
  • Lensar, Inc.$2K
  • Genentech USA, Inc.$161
  • Dompe US, Inc.$157
  • Cardinal Health 110 LLC$150
  • plus $388 from 10 others

What the payments were for

  • Consulting fees$4,2504%
  • Speaking & faculty fees$81,12585%
  • Travel & lodging$5,4526%
  • Food & beverage$4,7495%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,621 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$4,208,328
Medicare patients
633
Services billed
40,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost49$21,100
CombiganBrimonidine Tartrate/Timolol21$10,862
RestasisCyclosporine11$10,019
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$8,486
Travoprost20$3,116
Brimonidine Tartrate91$2,956
Latanoprost185$2,464
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$666
Dorzolamide Hcl13$374
Timolol Maleate39$219
Diclofenac Sodium14$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$143$41,98181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →